Alpha Blockers for BPH/BOO: Efficacy and Side Effects

Efficacy and Safety

All alpha blockers demonstrate equivalent efficacy for BPH symptom relief, with a 4-6 point improvement in AUA Symptom Index, but tamsulosin and alfuzosin are preferred due to superior tolerability with fewer cardiovascular side effects including fatigue, dizziness, and orthostatic hypotension 1
The American Urological Association recommends alpha blockers as a first-line treatment for BPH, with tamsulosin and alfuzosin being preferred options due to their superior tolerability profile 1
Efficacy differences between alpha blockers are clinically negligible, and choice should be based on side effect profile 1
Alpha blockers provide rapid symptom relief, but the exact onset of action may vary between agents 1

Uroselective agents, such as tamsulosin and alfuzosin, have significantly better tolerability than non-selective agents, such as doxazosin and terazosin, with lower rates of orthostatic hypotension, dizziness, and fatigue 1
Tamsulosin has the highest rate of ejaculatory dysfunction among alpha blockers, which should be discussed with patients before initiating treatment 1
Doxazosin and terazosin have higher rates of cardiovascular side effects, including orthostatic hypotension, dizziness, and fatigue, and should be used with caution in patients with cardiac risk factors 1

Tamsulosin 0.4 mg once daily is recommended as a first-line choice for most patients due to its equal efficacy to other agents, no dose titration required, and lowest cardiovascular side effect burden 1
Alfuzosin 10 mg once daily is recommended when ejaculatory function is a priority, due to its significantly lower rate of ejaculatory dysfunction compared to tamsulosin 1
Doxazosin and terazosin should not be relied upon for hypertension management, and separate antihypertensive therapy should be optimized in patients with concomitant hypertension 1

Oral alpha blockers, such as alfuzosin and tamsulosin, should be prescribed prior to voiding trial for acute urinary retention related to BPH, with patients completing at least 3 days of therapy before attempting trial without catheter 2
Combination therapy with 5-alpha reductase inhibitors reduces clinical progression of BPH more effectively than monotherapy in patients with enlarged prostates 2